CD274 and neoplasm: The results indicated that FMD+2‐DG+anti‐PD‐L1 treatment significantly slowed tumour growth and prolonged survival, suggesting that inhibiting glucose utilisation by tumour cells boosts anticancer immunity (Figure 8D).